Companies/CN/300347

HANGZHOU TIGERMED CONSULTING CO., LTD · 泰格医药

Income flow

Annual
300347 10-K Income StatementPeriod 2025-12-31Source 10-K
Net salesCNY 7B+4% Y/YRevenueCNY 7B+4% Y/YGross profitCNY 2BCost of revenueCNY 5BOperating profitCNY 1BOperating expensesCNY 864MNet profitCNY 888MTaxCNY 198MOperating expensesCNY 864M

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · CNY
By activity
By activityCNY 6.8B
  • 临床试验相关服务及实验室服务CNY 3.4B50.4%
  • 临床试验技术服务CNY 3.3B47.8%
  • 务及实验室服务其他业务服务CNY 119M1.8%
By geography
By geographyCNY 6.8B
  • 境内CNY 3.7B54.2%
  • 境外CNY 3.1B45.8%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.23%5y avgAverage dividend yield over the past five years — a smoother view than the latest print.0.52%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0.126PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.0.0%Shares outTotal shares currently outstanding (issued and not retired).737.9MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).646.0M
Dividend calendar
Ex-dividend
2026-07-10
Last cash
0.126 · 2026-07-10
Stock splits
  1. 1.5:12019-07-01

Valuation

Trailing PE 54.4 (2025-12-31)PE trend

Fiscal PE3

PeriodEPSClosePE
2025-12-311.0456.5454.4
2024-12-310.4754.15115.2
2023-12-312.3440.617.4

PE = stored close ÷ as-filed diluted EPS (annual 10-K / 20-F). Not a vendor PE series.